Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 - PubMed (original) (raw)

Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2

Steven Lehrer et al. In Vivo. 2020 Sep-Oct.

Abstract

Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2.

Materials and methods: We used the program AutoDock Vina Extended to perform the docking study.

Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08.

Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.

Keywords: ACE2; COVID-19; ivermectin; spike protein.

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest.

Figures

Similar articles

• A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
  Souza PFN, Lopes FES, Amaral JL, Freitas CDT, Oliveira JTA. Souza PFN, et al. Int J Biol Macromol. 2020 Dec 1;164:66-76. doi: 10.1016/j.ijbiomac.2020.07.174. Epub 2020 Jul 18. Int J Biol Macromol. 2020. PMID: 32693122 Free PMC article.
• Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
  Basu A, Sarkar A, Maulik U. Basu A, et al. Sci Rep. 2020 Oct 19;10(1):17699. doi: 10.1038/s41598-020-74715-4. Sci Rep. 2020. PMID: 33077836 Free PMC article.
• Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
  Teralı K, Baddal B, Gülcan HO. Teralı K, et al. J Mol Graph Model. 2020 Nov;100:107697. doi: 10.1016/j.jmgm.2020.107697. Epub 2020 Jul 23. J Mol Graph Model. 2020. PMID: 32739642 Free PMC article.
• Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection.
  Hill A, Garratt A, Levi J, Falconer J, Ellis L, McCann K, Pilkington V, Qavi A, Wang J, Wentzel H. Hill A, et al. Open Forum Infect Dis. 2021 Jul 6;8(11):ofab358. doi: 10.1093/ofid/ofab358. eCollection 2021 Nov. Open Forum Infect Dis. 2021. PMID: 34796244 Free PMC article. Retracted. Review.
• RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article.
  Zaidi AK, Dehgani-Mobaraki P. Zaidi AK, et al. J Antibiot (Tokyo). 2022 Feb;75(2):122. doi: 10.1038/s41429-021-00430-5. Epub 2021 Jun 15. J Antibiot (Tokyo). 2022. PMID: 34127807 Free PMC article. Retracted and republished. Review. No abstract available.

Cited by

• Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses.
  Scheim DE, Parry PI, Rabbolini DJ, Aldous C, Yagisawa M, Clancy R, Borody TJ, Hoy WE. Scheim DE, et al. Viruses. 2024 Apr 22;16(4):647. doi: 10.3390/v16040647. Viruses. 2024. PMID: 38675987 Free PMC article. Review.
• Binding behavior of receptor binding domain of the SARS-CoV-2 virus and ivermectin.
  Gossen KR, Zhang M, Nikolov ZL, Fernando SD, King MD. Gossen KR, et al. Sci Rep. 2024 Feb 2;14(1):2743. doi: 10.1038/s41598-024-53086-0. Sci Rep. 2024. PMID: 38302638 Free PMC article.
• Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.
  Velásquez PA, Hernandez JC, Galeano E, Hincapié-García J, Rugeles MT, Zapata-Builes W. Velásquez PA, et al. Clin Pharmacol. 2024 Jan 4;16:1-25. doi: 10.2147/CPAA.S429064. eCollection 2024. Clin Pharmacol. 2024. PMID: 38197085 Free PMC article. Review.
• Microfluidic Diffusion Sizing Applied to the Study of Natural Products and Extracts That Modulate the SARS-CoV-2 Spike RBD/ACE2 Interaction.
  Fauquet J, Carette J, Duez P, Zhang J, Nachtergael A. Fauquet J, et al. Molecules. 2023 Dec 13;28(24):8072. doi: 10.3390/molecules28248072. Molecules. 2023. PMID: 38138562 Free PMC article.
• Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.
  Scheim DE, Vottero P, Santin AD, Hirsh AG. Scheim DE, et al. Int J Mol Sci. 2023 Dec 1;24(23):17039. doi: 10.3390/ijms242317039. Int J Mol Sci. 2023. PMID: 38069362 Free PMC article. Review.

References

1. 1. Goa KL, McTavish D, Clissold SP. Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991;42(4):640–658. doi: 10.2165/00003495-199142040-00007. - DOI - PubMed
2. 1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787. - DOI - PMC - PubMed
3. 1. Bray M, Rayner C, Noel F, Jans D, Wagstaff K. Ivermectin and Covid-19: A report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res. 2020;178:104805. doi: 10.1016/j.antiviral.2020.104805. - DOI - PMC - PubMed
4. 1. FDA: F.D.A. Letter to stakeholders: Do not use ivermectin intended for animals as treatment for covid-19 in humans. Available at: https://wwwfdagov/animal-veterinary/productsafety-information/fda-letter-stakeholders-do-not-use-ivermectinintended-animals-treatment-covid-19-humans [Last accessed on 18 Jun 2020]
5. 1. Servick K, Enserink M. The pandemic’s first major research scandal erupts. Science. 2020;368(6495):1041–1042. doi: 10.1126/science.368.6495.1041. - DOI - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • PubMed Central

• Miscellaneous

  • NCI CPTAC Assay Portal